+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
R

Actively Recruiting

Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
186 locations
E

Actively Recruiting

Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
89 locations
E

Actively Recruiting

Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.

Age: 12Years +All GendersPhase 2
186 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.

Age: 18Years - 75YearsAll GendersPhase 3
237 locations

1-10 of 30

1